Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
September 05, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
August 04, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
August 03, 2023 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022 CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for...
July 28, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
June 05, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
May 31, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
May 04, 2023 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in...
May 02, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
April 26, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...